IV Placement in Stroke Patients: Arm Selection Guidelines

Rationale for Using the Non-Paretic Arm

The non-paretic arm is preferred for IV placement in stroke patients as it preserves the affected arm for rehabilitation activities and functional recovery 1
Using the unaffected arm helps avoid potential complications in the paretic arm which may have compromised circulation, sensation, or movement 2, 3

IV access is critical for administering thrombolytic therapy (r-tPA), which is the primary treatment for acute ischemic stroke within the first 3-4.5 hours 1, 3
Proper IV placement is essential for administration of r-tPA (0.9 mg/kg, maximum dose 90 mg) in eligible patients 1
Proper IV placement is essential for delivery of early aspirin therapy (160-325 mg) within 48 hours of stroke onset 2, 4
Proper IV placement is essential for prophylactic anticoagulation in patients with restricted mobility 3

If IV access cannot be established in the non-paretic arm, consider alternative sites such as the external jugular vein or placement of a central line if absolutely necessary 5
When using the paretic arm becomes unavoidable, extra care should be taken to use the most distal site possible to preserve proximal veins 2
When using the paretic arm becomes unavoidable, extra care should be taken to monitor the IV site frequently for infiltration or complications 3
When using the paretic arm becomes unavoidable, extra care should be taken to remove the IV as soon as clinically appropriate 5

Time is critical in stroke management - "time is brain" - so IV placement should be accomplished quickly to facilitate timely administration of thrombolytics 1, 3
The NINDS trials demonstrated that patients treated with IV r-tPA within 3 hours were at least 30% more likely to have minimal or no disability at 3 months 6
Delays in establishing IV access can significantly impact treatment outcomes and should be minimized 3

Do not delay thrombolytic treatment for difficult IV access - consider alternative access methods if needed 3

Ensure IV access remains patent for administration of medications and fluids throughout the acute treatment phase 3